Many mAbs target LAG3, most of which are undergoing clinical trials, including IMP321(first LAG3 fusion protein) and relatlimab (first LAG3 mAb), and show good potential in tumor immunotherapy (58). This evidence concerns the gene LAG3 and neoplasm.